Trial of long-term rTMS therapy for intractable neuropathic pain

Trial of long-term rTMS therapy for intractable neuropathic pain - TMS-P-07

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs052190110

Enrollment

Registered

2020-02-20

Start date

2020-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain chronic pain, intractable pain

Interventions

repetitive transcranial magnetic stimulation

D050781

noninvasive brain stimulation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with neuropathic pain longer than 6 months after onset. 2) Baseline VAS of pain intensity: 40 to 95/100 mm 3) Patients with currently prescribed medication for NP or a history of being prescribed multiple medications for NP without achieving pain control 4) Patients with continuous pain at upper extremity 5) Age >= 20 years 6) Patients with written consent for participation in this study 1) Average of pain diary (NRS) 1 week before intervention: >= 4 2) Average of VAS 1 week before intervention: >= 40 mm

Exclusion criteria

Exclusion criteria: 1) Patients with dementia (MMSE = 1) Patients who are unable to comply combination prohibited or combination restricted therapies during the observation period 2) Patients who are able to fill in the evaluation forms for less than five days during the observation period 3) Others not applicable person determined by the investigators

Design outcomes

Primary

Measure	Time frame
Decrease in the weekly average of pain diary (NRS) at each week (week 1 to 8) compared with baseline	—

Secondary

Measure	Time frame
1) Pain diary Decrease rate of the weekly average of pain diary (NRS) at each time point compared with baseline Ratio of patients that showed >= 2 decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 4 decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 30% decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 50% decrease in the weekly average of pain diary (NRS) at week 8 2) VAS Decrease and decrease rate of VAS at each time point compared with baseline Ratio of patients that showed >= 20 mm decrease in VAS at week 9 Ratio of patients that showed >= 40 mm decrease in VAS at week 9 Ratio of patients that showed >= 30% decrease in VAS at week 9 Ratio of patients that showed >= 50% decrease in VAS at week 9 3) SF-MPQ2 Decrease and decrease rate of SF-MPQ2 total score at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 total score at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 total score at week 9 Decrease and decrease rate of SF-MPQ2 each subscale score (continuous pain, intermittent pain, neuropathic pain, affective descriptors) at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 each subscale score at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 each subscale score at week 9 Decrease and decrease rate of SF-MPQ2 each item at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 each item at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 each item at week 9 4) VAS immediately after intervention Decrease and decrease rate of VAS immediately after each intervention compared with baseline Decrease and decrease rate of VAS immediately after intervention during induction period (day 1 to 5) compared with baseline Ratio of patients that showed >= 10 mm decrease	—

Measure

Time frame

1) Pain diary Decrease rate of the weekly average of pain diary (NRS) at each time point compared with baseline Ratio of patients that showed >= 2 decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 4 decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 30% decrease in the weekly average of pain diary (NRS) at week 8 Ratio of patients that showed >= 50% decrease in the weekly average of pain diary (NRS) at week 8 2) VAS Decrease and decrease rate of VAS at each time point compared with baseline Ratio of patients that showed >= 20 mm decrease in VAS at week 9 Ratio of patients that showed >= 40 mm decrease in VAS at week 9 Ratio of patients that showed >= 30% decrease in VAS at week 9 Ratio of patients that showed >= 50% decrease in VAS at week 9 3) SF-MPQ2 Decrease and decrease rate of SF-MPQ2 total score at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 total score at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 total score at week 9 Decrease and decrease rate of SF-MPQ2 each subscale score (continuous pain, intermittent pain, neuropathic pain, affective descriptors) at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 each subscale score at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 each subscale score at week 9 Decrease and decrease rate of SF-MPQ2 each item at each time point compared with baseline Ratio of patients that showed >= 30% decrease in SF-MPQ2 each item at week 9 Ratio of patients that showed >= 50% decrease in SF-MPQ2 each item at week 9 4) VAS immediately after intervention Decrease and decrease rate of VAS immediately after each intervention compared with baseline Decrease and decrease rate of VAS immediately after intervention during induction period (day 1 to 5) compared with baseline Ratio of patients that showed >= 10 mm decrease

—

Contacts

Public ContactKoichi Hosomi

Osaka University Hospital

k-hosomi@nsurg.med.osaka-u.ac.jp+81-6-6879-3652

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026